Murray, M;
McIntosh, M;
Atkinson, C;
Muhungu, T;
Wright, E;
Chatterton, W;
Gandy, M;
(2021)
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.
Journal of Infection
, 82
(5)
pp. 170-177.
10.1016/j.jinf.2021.03.010.
Preview |
Text
Reeves_Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay_VoR.pdf - Published Version Download (1MB) | Preview |
Abstract
OBJECTIVES: To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-2 neutralisation by human sera, and further to establish whether measuring responses against the RBD of S was a diagnostically useful proxy for responses against the whole S protein. METHODS: Serum samples from 30 patients were assayed for anti-NP responses, for ‘neutralisation’ by the surrogate neutralisation assay and for neutralisation by SARS-CoV-2 S pseudotyped virus assays utilising two target cell lines. Correlation between assays was measured using linear regression. RESULTS: The responses observed within the surrogate neutralisation assay demonstrated an extremely strong, highly significant positive correlation with those observed in both pseudotyped virus assays. CONCLUSIONS: The tested ELISA-based surrogate assay provides an immunologically useful measure of functional immune responses in a much quicker and highly automatable fashion. It also reinforces that detection of anti-RBD neutralising antibodies alone is a powerful measure of the capacity to neutralise viral infection.
| Type: | Article |
|---|---|
| Title: | Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jinf.2021.03.010 |
| Publisher version: | https://doi.org/10.1016/j.jinf.2021.03.010 |
| Language: | English |
| Additional information: | © 2021 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association under a Creative Commons license (https://creativecommons.org/licenses/by/4.0/). |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10124568 |
Archive Staff Only
 |
View Item |
